Everyday Mart, Roxy Square, Katong, Announces Major Brand Development in Travel, Food Beverage and Music Devices

The new brand initiative reflects the company’s ongoing focus on innovation, growth, and long-term vision in the Travel, food beverage and music devices sector. With this development, Everyday Mart, Roxy Square, Katong aims to strengthen its position and adapt to the evolving market needs, reinforcing its core values and commitment to excellence.

Everyday Mart, Roxy Square, Katong, a recognized leader in travel food, beverage and music devices, is excited to announce a significant new development in its brand evolution. This move signals the company’s continued dedication to tourism and hospitality, reinforcing its position as a forward-thinking entity within the travel food, beverage and music devices sector.

The new initiative will improve travel food, beverage and music devices supporting Everyday Mart’s broader goals of providing food, drinks and music to travelers and improving customer experience. Here, there is a demand for travel and Everyday Mart can provide food and drinks to international travelers and bloggers. With the rise of social media platforms, here photographers and videographers are hard at work. There are more travel shows in Disney plus and Netflix. The travel industry has expanded to a higher level.

“We are proud to take this next step in our brand’s journey,” said Dzulhafiez, Store Assistant “This announcement underscores our long-term vision and our commitment to maintaining our leadership in travel food beverage and music sector.”

With this latest brand development, Everyday Mart is set to build on its leader in travel food, as it continues to provide food, drinks and music to world travelers. Here, food shortage across the world is getting higher and is important for Singapore to be a leader in food.

For more information on Everyday Mart and its latest brand initiative, visit https://chinatown.sg/shop/everyday-mart/

About Everyday Mart

Providing food, drinks and music to international travelers, opening everyday key, providing snacks, drinks and music devices and featured on 3 online travel shows.

Media Contact
Company Name: Everyday Mart
Email: Send Email
Country: Singapore
Website: https://chinatown.sg/shop/everyday-mart/

Middleton Painting Enhances Homes with Professional Painting Services in Bartlett

Middleton Painting Enhances Homes with Professional Painting Services in Bartlett
Middleton Painting, a trusted name in professional painting services, continues to provide exceptional craftsmanship and high-quality finishes for residential properties throughout Bartlett. With a dedication to precision and excellence, the company ensures that every project meets the highest industry standards.

Specializing in both interior and exterior painting, Middleton Painting offers tailored solutions designed to enhance the beauty and longevity of residential properties. As leading House Painters Bartlett, the team delivers superior workmanship, transforming homes with meticulous attention to detail and premium-grade materials.

Middleton Painting prioritizes customer satisfaction by utilizing durable paints and advanced techniques to achieve long-lasting results. Every project is managed with professionalism, ensuring a seamless and efficient painting process. Whether revitalizing interiors or refreshing exteriors, the expertise of these Home Painters Bartlett guarantees outstanding results that elevate property aesthetics and value.

For homeowners seeking a skilled Bartlett Painter, Middleton Painting remains the top choice for quality-driven painting solutions. With years of experience and a commitment to excellence, the company continues to set the standard for professional painting services in Bartlett and the surrounding areas.

Media Contact
Company Name: Middleton Painting
Contact Person: Dennis Middleton
Email: Send Email
Phone: (901) 352-0202
Address:95 Stephen Hill Road Atoka
City: Memphis
State: Tennessee
Country: United States
Website: https://www.middletonpaintingmemphis.com/

Trevi Pools and Spas Kelowna Offers Custom Pool Liners and Expert Spring Pool Opening Services for 2025 Season

Kelowna, BC – April 23, 2025 – As the Okanagan gears up for warmer weather, Trevi Pools and Spas Kelowna is helping homeowners get their pools spring-ready with premium custom pool liners and professional pool opening services for both in-ground and above-ground pools.

Manufactured with precision at Trevi’s advanced facility in Mirabel, Quebec, Trevi’s pool liners are built to perform and designed to last. Each liner is custom-made to order to ensure a perfect fit—crafted using 100% recycled virgin vinyl that resists UV fading and stands up to the harsh Canadian climate.

For in-ground pools, customers can choose from 42″ or 48″ liners, with or without decorative borders, and optional non-slip embossed textures ideal for full-width steps.

Kelowna Above-ground pool owners will also enjoy the benefits of high-durability vinyl, treated to withstand prolonged sun exposure. Every liner is computer-designed and manufactured to the highest standards, ensuring a seamless, watertight fit and long-lasting beauty.

“We know that opening your pool for the season should be exciting, not stressful,” said Paul Tallon, owner of Trevi Pools and Spas. “That’s why we offer full-service spring openings in Kelowna—handling everything from removing covers and reassembling equipment to balancing water chemistry and inspecting systems.”

Whether you need a liner replacement, a new pool installation, or a reliable team to open your pool for the season, Trevi’s local experts are ready to help. Trevi Pools and Spas combines over 30 years of pool experience with Canadian-made products, eco-conscious practices, and unmatched customer service. Financing is available for Pool and liners.

About Trevi Pools and Spas Kelowna

Trevi Pools and Spas is a trusted name in pool and spa solutions across Canada, with locations in Kelowna, BC and Calgary, AB. All liners and many pool components are manufactured at Trevi’s facility in Mirabel, Quebec, ensuring quality control from production to installation. Trevi offers in-ground and above-ground pool products, custom liners, pool openings, and more—with financing options available to make your dream backyard a reality.

Media Contact
Company Name: Trevi Pools and Spas
Contact Person: Bre Tallon
Email: Send Email
Phone: 250-258-8202
City: Kelowna
State: BC
Country: Canada
Website: https://trevipoolsandspas.ca

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Trevi Pools and Spas Kelowna Offers Custom Pool Liners and Expert Spring Pool Opening Services for 2025 Season

Jordan Turnbow is Quietly Redefining What Real Estate Leadership Looks Like

In an industry driven by flash, fast flips, and hype-driven promises, Jordan Turnbow is taking a different path—one built on values, vision, and execution. As co-founder of Automated REI Group, Turnbow isn’t just teaching real estate strategy—he’s rebuilding how leadership in this space should look: focused, mission-driven, and grounded in results.

At the core of Turnbow’s leadership style is a belief that investors don’t just need deals—they need guidance, protection, and someone who will walk the path with them, not just sell them a roadmap. That belief has shaped every part of Automated REI Group’s client experience, where his team handles 95% of the work—from sourcing to closing—while keeping clients fully involved in each key decision.

“People are tired of being sold. They want real leadership. They want someone who’s actually been in the trenches,” Turnbow says. “That’s why I stay close to the process—because that’s where trust is built.”

Turnbow leads with structure, but also with service. His mission is to help working professionals and new investors access real estate the right way—not just for profit, but for peace of mind. That mindset has resonated with clients across the country, many of whom are building their first property portfolio while still working full-time jobs or raising families.

He’s also deeply focused on the bigger picture—solving the affordable housing gap one investor at a time. By helping clients invest in Section 8 rentals, Turnbow is aligning two outcomes that rarely meet: wealth building and community impact.

“This isn’t just business—it’s personal,” Turnbow explains. “We’re putting families in homes and helping investors create something real. That’s what drives me.”

With growing demand and a reputation for being one of the few voices that still does the work, Jordan Turnbow is proving that leadership in real estate doesn’t need to be loud—it needs to be honest.

For media inquiries or to connect with Jordan, visit www.automatedreigroup.com

Media Contact
Company Name: Automated REI Group
Contact Person: Jordan Turnbow
Email: Send Email
Phone: (346) 510-4607
City: Houston
State: Texas
Country: United States
Website: www.automatedreigroup.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Jordan Turnbow is Quietly Redefining What Real Estate Leadership Looks Like

Automated REI Group Helps Investors Build Wealth While Solving a Real Housing Crisis

With rising home prices and a growing shortage of affordable rentals, Automated REI Group is helping solve two major problems at once: making real estate investing more accessible, while helping families secure safe, stable housing through the Section 8 program.

Founded by real estate investor Jordan Turnbow, the Houston-based firm offers a structured, full-support model that guides clients through the process of acquiring rental properties that qualify for government-subsidized housing. The company’s approach appeals to both first-time investors and seasoned buyers looking for a smarter, more convenient way to expand their portfolio.

“Most investors don’t want another job—they want consistency, protection, and peace of mind,” says Turnbow. “We’ve built a system that delivers that while also creating real impact.”

Unlike traditional real estate models, Automated REI Group focuses entirely on Section 8 housing—a strategy often misunderstood, but increasingly in demand. With rent paid directly by local housing authorities, the Section 8 program offers a layer of security many investors now see as essential.

The company manages the full process for clients, including:

  • Property sourcing and analysis
  • Offer support and inspections
  • Landlord approval through local housing authorities
  • Tenant placement and property management setup

“We’re not a course or coaching program,” Turnbow adds. “We’re a hands-on partner that helps you get the deal done the right way—from day one.”

As housing affordability continues to decline, Automated REI Group is positioning its clients to not only build real assets, but also be part of the solution. The company is currently working with investors across the country, with a goal of helping over 1,000 families access clean, safe housing by 2026.

For more information or to book a consultation, visit www.automatedreigroup.com

Media Contact
Company Name: Automated REI Group
Contact Person: Jordan Turnbow
Email: Send Email
Phone: (346) 510-4607
City: Houston
State: Texas
Country: United States
Website: www.automatedreigroup.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Automated REI Group Helps Investors Build Wealth While Solving a Real Housing Crisis

Myhappyworldshop Launches Personalized Art Service to Transform Photos into Timeless Portraits

Introduction to Custom Portraits

Custom portraits are a unique and personalized way to preserve memories and cherish loved ones. At our studio, we specialize in creating custom portrait paintings from photos. Our skilled artists use high-quality materials and techniques to bring your vision to life. Whether you’re looking for a family portrait, pet portrait, or single portrait, we can help you create a stunning piece of artwork that will be treasured for a lifetime. Our custom portrait painting service includes a range of mediums, such as oil painting, acrylic, and color pencil sketch, to ensure that your portrait is truly one-of-a-kind.

Why Choose Handmade Portraits?

There’s something irreplaceable about a handmade portrait. Beyond a simple image, it captures emotion, memory, and story—preserved in brush strokes and artistic detail. When you invest in a custom hand painted portrait, you’re not just buying art; you’re securing a meaningful keepsake.

Each artwork is a one-of-a-kind creation, crafted with care, emotion, and precision by our skilled artists. The passion for creativity that goes into each portrait ensures meticulous attention to detail. From the first sketch to the final touch, the creation process is personal, involving consultations and multiple approvals to ensure the portrait truly reflects your vision. Whether it’s a family moment or a beloved pet, these portraits carry legacy and sentimental value that last for generations.

Choosing the Perfect Photo

Your journey begins with selecting the right image. Choose a photo that embodies the subject’s character and emotion. Ensure the photo is high-resolution and well-lit to provide the best reference for your custom portrait.

Consider the setting, background, and lighting—these elements impact the atmosphere of the final piece. Our team can assist with minor enhancements or edits, like adjusting background elements, so your image is portrait-ready.

Whether it’s a pet portrait, a child’s portrait, or a multi-subject family piece, we ensure your photo becomes the foundation of an unforgettable artwork. Creating portraits of children holds special emotional significance, capturing precious moments and preserving cherished memories.

Exploring Different Portrait Styles

There’s no one-size-fits-all when it comes to portrait styles. Each medium offers a unique visual language:

  • Oil Paintings: Rich in color and timeless appeal, oil portraits bring depth and vibrancy.

  • Watercolor Art: Light, delicate, and ethereal—great for soft, emotional portrayals.

Our expert artists play a crucial role in creating high-quality portraits, ensuring meticulous attention to detail and unique techniques. We offer a variety of styles, from realistic to impressionistic, so you can find the perfect medium to match your vision and décor.

Why Choose a Professional Artist

Choosing a professional artist for your custom portrait is essential to ensure that your artwork is of the highest quality. Our talented artists have years of experience in creating handmade portraits, and they use their expertise to capture the subject’s personality and spirit. We understand that every person is unique, and our artists take the time to get to know you and your vision to create a custom portrait that exceeds your expectations. By working with a professional artist, you can be assured that your portrait will be a masterpiece that will be cherished for generations to come. Our artists use a range of techniques, including realism and creativity, to bring your photo to painting.

Pet Portraits: Celebrate Furry Companions

Pets hold a special place in our lives, and capturing their spirit through a custom pet portrait is a beautiful tribute. Whether it’s the playful gleam in their eye or the texture of their coat, our artists meticulously replicate every detail.

Choose from a range of mediums—oil, charcoal, or pencil sketch—to reflect your pet’s character. From solo pet portraits to full family compositions including pets, we offer personalized options tailored to your needs.

Our customers often share heartfelt stories about how their pet portrait has brought joy, comfort, or a smile during times of remembrance. These artworks also make thoughtful gifts for pet lovers, friends, and family.

Every portrait is crafted with durable materials, ensuring your tribute lasts for years to come. And most importantly, each piece is made with care, compassion, and artistic excellence.

From Photo to Painting: Bring Memories to Life

Transforming your cherished photograph into a beautiful handmade painting is easier than ever. Whether you prefer the classic texture of oil or the dreamy tones of watercolor, our artists breathe life into your images.

We also offer personalized edits—such as combining multiple photos or changing backgrounds as requested—to tailor the piece exactly how you envision it. Every client receives a preview of their painting before final approval and shipment, allowing for adjustments and ensuring full satisfaction.

This makes our photo-to-painting service ideal for special occasions like anniversaries, birthdays, memorials, or holidays. The final product is delivered securely to your home, ensuring it arrives in perfect condition.

The Portrait Creation Process

Our process is straightforward and collaborative:

  1. Upload Your Photo: Send us your chosen image via email or our website submission form.

  2. Select Style & Medium: Choose from oil painting, pencil sketch, watercolor, or others.

  3. Customization & Edits: Request any changes such as background adjustments or combining subjects.

  4. Review the Preview: We’ll send a digital preview for your feedback.

  5. Approve & Ship: Once approved, we ship your handmade portrait securely with tracking.

We provide multiple checkpoints for customer feedback, ensuring transparency and a final product you’ll love. If you have any questions or need assistance, please contact our support team.

Why Handmade Portraits Make the Perfect Gift

Looking for a meaningful gift? A personalized portrait shows deep thought and emotional significance. It’s not just a present—it’s a memory made tangible.

Perfect for weddings, retirements, birthdays, memorials, housewarmings, or any special occasion, these artworks are deeply personal and heartfelt. You get to choose everything—from size and style to subject and framing—making your gift completely unique.

A custom portrait is a timeless reminder of love, appreciation, and shared history. It’s more than a gift—it’s a lasting tribute.

Customer Testimonials and Reviews

Don’t just take our word for it – our customers rave about our custom portrait painting service. We have a collection of testimonials and reviews from satisfied customers who have used our service to create stunning hand painted portraits, handmade paintings, and custom portrait paintings. Our customers appreciate the attention to detail, the quality of the artwork, and the excellent customer service they receive. We take pride in delivering exceptional results and ensuring that our customers are completely satisfied with their portrait. Whether you’re looking for a gift for loved ones or a way to cherish memories, our custom portrait painting service is the perfect solution.

Hassle-Free Ordering & Shipping

We aim to make your experience smooth from start to finish:

  • Shipping Worldwide: Reliable, insured shipping with full tracking.

  • Timelines: We deliver typically within 14 to 23 days, ensuring efficiency and reliability.

  • Secure Packaging: Your artwork is packed with care to prevent damage.

  • Satisfaction Guarantee: If you’re not happy, we’ll refund or replace—no questions asked.

Our support team is available to help at any stage—whether you have questions about artwork, shipping, or customization.

Secure Payment Options

At our studio, we understand the importance of secure payment options. We offer a range of payment methods, including PayPal, to ensure that your transaction is safe and secure. Our website is designed to protect your personal and financial information, and we use the latest technology to prevent any unauthorized access. We also offer a guarantee on our custom portrait paintings, so you can be assured that you’re getting a high-quality piece of artwork. Our secure payment options give you peace of mind, allowing you to focus on creating a stunning custom portrait that will be treasured for a lifetime.

How to Care for Your Portrait

To keep your portrait in pristine condition:

  • Keep it away from direct sunlight to prevent fading.

  • Clean gently with a dry cloth—never use water or harsh cleaners.

  • Consider framing with UV-protective glass.

  • Store in a cool, dry place when not displayed.

With proper care, your custom handmade portrait will remain a cherished piece for generations. Maintaining the beauty of your artwork through careful display, regular dusting, and high-quality framing ensures its aesthetic quality endures over time.

Inspiration and Artist Support

Need guidance? Our artists and support staff are here to assist with:

  • Photo selection

  • Style and medium advice

  • Customization suggestions

  • Progress updates and revisions

You’re never alone in the process. From concept to creation, we’re dedicated to helping you turn memories into masterpieces.

Explore our portfolio online to view sample work, submit photos, and get inspired by the many ways others have turned cherished images into beautiful, handmade portraits. Our services are available to customers around the world.

Media Contact
Company Name: My Happy World Shop
Contact Person: Ajun Abraham
Email: Send Email
Address:21 Blakes rd
City: Belfast
State: Christchurch
Country: New Zealand
Website: https://myhappyworldshop.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myhappyworldshop Launches Personalized Art Service to Transform Photos into Timeless Portraits

MedcareMSO Unveils Top 5 Billing Mistakes in Pain Management and Strategies to Prevent Them

Billing in pain management can be tricky. It involves many steps, codes, and rules. Mistakes can lead to denied claims, lost revenue, and even legal issues. To help you avoid these problems, we’ve put together a list of the top 5 common billing mistakes in pain management and tips on how to avoid them.

1. Incorrect Coding

One of the most common mistakes is using the wrong codes. Pain management involves many procedures, like injections, nerve blocks, and medication management. Each of these has specific codes. Using the wrong code can lead to claim denials.

How to Avoid:

  • Stay updated with the latest coding changes. Codes can change every year, so make sure your team is trained on the new codes.
  • Double-check the codes before submitting claims. Use coding software or tools to help you find the correct codes.
  • If you’re unsure, consult with a coding expert or a professional medical coder.

2. Not Documenting Properly

Proper documentation is key to successful billing. If the documentation is incomplete or unclear, insurance companies may deny the claim. For example, if you don’t document the medical necessity of a procedure, the claim might be rejected.

How to Avoid:

  • Make sure all patient records are complete and accurate. Include details like the patient’s symptoms, diagnosis, and the reason for the procedure.
  • Use templates or checklists to ensure you don’t miss any important information.
  • Train your staff on proper documentation practices. Everyone involved in patient care should know what needs to be documented.

3. Billing for Non Covered Services

Some services may not be covered by insurance. For example, certain types of injections or treatments might not be approved for specific conditions. If you bill for these services, the claim will likely be denied.

How to Avoid:

  • Verify insurance coverage before performing any procedure. Check with the patient’s insurance company to see if the service is covered.
  • Inform the patient if a service is not covered. They may choose to pay out-of-pocket or opt for a different treatment.
  • Keep a list of commonly non-covered services and share it with your team.

4. Duplicate Billing

Duplicate billing happens when the same service is billed more than once. This can happen by accident, but it can lead to claim denials and even accusations of fraud.

How to Avoid:

  • Use a billing system that flags duplicate entries. Many modern billing software programs can detect if the same service is being billed twice.
  • Review claims carefully before submitting them. Make sure each service is only billed once.
  • Train your billing staff to be careful when entering data. A simple typo can lead to duplicate billing.

5. Ignoring Denied Claims

When a claim is denied, some practices simply move on without addressing the issue. This can lead to lost revenue and unresolved billing problems.

How to Avoid:

  • Track all denied claims and find out why they were denied. Common reasons include incorrect coding, missing information, or lack of medical necessity.
  • Appeal denied claims when appropriate. If you believe the claim was wrongly denied, follow the insurance company’s appeal process.
  • Use denial management software to help you track and resolve denied claims more efficiently.

Bonus Tip: Stay Educated and Updated

The world of medical billing is always changing. New codes, rules, and regulations are introduced regularly. Staying educated and updated is crucial to avoiding billing mistakes.

How to Stay Updated:

  • Attend billing and coding workshops or webinars.
  • Subscribe to industry newsletters or journals.
  • Join professional organizations related to pain management billing services. These groups often provide resources and updates.

Conclusion

Billing mistakes in pain management can be costly, but they are often preventable. By focusing on correct coding, proper documentation, verifying insurance coverage, avoiding duplicate billing, and addressing denied claims, you can reduce errors and improve your revenue cycle.

Remember, billing is a team effort. Make sure everyone in your practice, from the front desk to the billing department, is trained and aware of these common mistakes. With the right practices in place, you can minimize errors, improve patient satisfaction, and ensure your practice runs smoothly.

By taking these steps, you’ll not only avoid common billing mistakes but also create a more efficient and effective pain management practice.

Media Contact
Company Name: Medcaremso
Contact Person: Jeremy Carter
Email: Send Email
City: Irvine
Country: United States
Website: https://medcaremso.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: MedcareMSO Unveils Top 5 Billing Mistakes in Pain Management and Strategies to Prevent Them

Sickle Cell Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s “Sickle Cell Disease Pipeline Insights 2025” report provides comprehensive insights about 55+ companies and 60+ drugs in the Sickle Cell Disease Competitive landscape. It covers the Sickle Cell Disease Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Sickle Cell Disease Treatment Landscape. Click here to read more @ Sickle Cell Disease Pipeline Outlook

Key Takeaways from the Sickle Cell Disease Pipeline Report

  • In April 2025, Kamau Therapeutics announced a study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.
  • In April 2025, Novartis Pharmaceuticals conducted a phase III study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.
  • In April 2025, Novo Nordisk A/S organized a study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance.
  • DelveInsight’s Sickle Cell Disease pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Sickle Cell Disease treatment.
  • The leading Sickle Cell Disease Companies such as Pfizer, Editas Medicine, Roche, Quercis Pharma, Graphite Bio, Beam Therapeutics Inc, GlaxoSmithKline, Agios Pharmaceuticals, BRL Medicine, Oryzon Genomics, CorrectSequence Therapeutics, GluBio Therapeutics, Base Therapeutics and others.
  • Promising Sickle Cell Disease Pipeline Therapies such as Siplizumab, Daratumumab, Alemtuzumab, Sirolimus, ITU512, BEAM-101, Crizanlizumab, Etavopivat, Epeleuton, Voxelotor and others.

Stay informed about the cutting-edge advancements in Sickle Cell Disease Treatments. Download for updates and be a part of the revolution in Genetic Disorders Care @ Sickle Cell Disease Clinical Trials Assessment

Sickle Cell Disease Marketed Therapies

  • Vertex Pharmaceuticals: CASGEVY

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including APOL1-mediated kidney disease, acute and neuropathic pain, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.

CASGEVY™ is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient’s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate VOCs for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved for certain indications in multiple jurisdictions for eligible patients.

  • Emmaus Medical Inc.: ENDARI

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. The company is engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan diseases. The initial efforts have focused on treatments for Sickle Cell Disease, a genetic disorder. Emmaus’s lead commercial product is Endari®, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

ENDARI [L-glutamine oral powder] is indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older. ENDARI is an amino acid indicated to reduce the acute complication of sickle cell disease in adult. The mechanism of action of the amino acid L-glutamine in treating sickle cell disease (SCD) is not fully understood. Oxidative stress phenomena are involved in the pathophysiology of SCD. Sickle red blood cells (RBCs) are more susceptible to oxidative damage than normal RBCs, which may contribute to the chronic hemolysis and vaso-occlusive events associated with SCD. The pyridine nucleotides, NAD+ and its reduced form NADH, play roles in regulating and preventing oxidative damage in RBCs. L-glutamine may improve the NAD redox potential in sickle RBCs through increasing the availability of reduced glutathione.

The Sickle Cell Disease Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Sickle Cell Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sickle Cell Disease Treatment.
  • Sickle Cell Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Sickle Cell Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sickle Cell Disease market.

Emerging Sickle Cell Disease Drugs Under Different Phases of Clinical Development Include:

  • RL 101: BRL Medicine
  • ORY-300:1 Oryzon Genomics
  • GSK 4172239D: GlaxoSmithKline
  • AG-946: Agios Pharmaceuticals
  • BEAM-101: Beam Therapeutics Inc.
  • Nula-cel: Graphite Bio
  • RG 6107: Roche
  • Isoquercetin: Quercis Pharma
  • Renizgamglogene autogedtemcel: Editas Medicin
  • Inclacumab: Pfizer
  • L-glutamine: Emmaus Medical, Inc
  • CASGEVY: Vertex Pharmaceuticals
  • ESCAPE: Beam Therapeutic
  • IHP-102: IHP Therapeutics
  • HBI-002: Hillhurst Biopharmaceuticals
  • BEAM101: Beam Therapeutics
  • EPI01: Novo Nordisk
  • VIT-2763: CSL Vifor
  • Inclacumab: Pfizer
  • L-glutamine: Emmaus Medical
  • Oxbryta: Pfizer
  • Exagamglogene autotemcel: CRISPR Therapeutics/Vertex Pharmaceuticals
  • Mitapivat: Agios Pharmaceuticals
  • Canakinumab: Novartis
  • ALXN1820: Alexion Pharmaceuticals
  • Crovalimab: Chugai Pharmaceutical/Roche
  • EDIT 301: Editas Medicine
  • BIVV003: Sangamo Therapeutics
  • BEAM101: Beam Therapeutics
  • Hemopexin: CSL Behring

Get a detailed analysis of the latest innovations in the Sickle Cell Disease pipeline. Explore DelveInsight’s expert-driven report today! @ Sickle Cell Disease Unmet Needs

Sickle Cell Disease Companies

Pfizer, Editas Medicine, Roche, Quercis Pharma, Graphite Bio, Beam Therapeutics Inc, GlaxoSmithKline, Agios Pharmaceuticals, BRL Medicine, Oryzon Genomics, CorrectSequence Therapeutics, GluBio Therapeutics, Base Therapeutics, and others.

Sickle Cell Disease Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intranasal

• Intrathecal

• Intravenous

• Oral

• Oral/Intravenous

• Parenteral

• Subcutaneous

• Subcutaneous/Intramuscular

• Transdermal

Sickle Cell Disease Products have been categorized under various Molecule types, such as

• Antisense oligonucleotide

• Gene therapy

• Hormones

• Neuropeptides

• Oligonucleotides

• Small Molecule

• Triglyceride

Sickle Cell Disease Pipeline Analysis

  • The report provides detailed insights about companies that are developing therapies for the treatment of Sickle Cell Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sickle Cell Disease Treatment.
  • Sickle Cell Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Sickle Cell Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sickle Cell Disease market.
  • The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Discover the latest advancements in Sickle Cell Disease Treatment by visiting our website. Stay informed about how we’re transforming the future of Genetic Disorders @ Sickle Cell Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Sickle Cell Disease Pipeline Report

  • Coverage- Global
  • Sickle Cell Disease Companies- Pfizer, Editas Medicine, Roche, Quercis Pharma, Graphite Bio, Beam Therapeutics Inc, GlaxoSmithKline, Agios Pharmaceuticals, BRL Medicine, Oryzon Genomics, CorrectSequence Therapeutics, GluBio Therapeutics, Base Therapeutics and others.
  • Sickle Cell Disease Pipeline Therapies- Siplizumab, Daratumumab, Alemtuzumab, Sirolimus, ITU512, BEAM-101, Crizanlizumab, Etavopivat, Epeleuton, Voxelotor and others.
  • Sickle Cell Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Sickle Cell Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Sickle Cell Disease Pipeline on our website @ Sickle Cell Disease Emerging Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Sickle Cell Disease (SCD): Overview
  4. Sickle Cell Disease -Analytical Perspective: In-depth Commercial Assessment
  5. Competitive Landscape
  6. Sickle Cell Disease: Company and Product Profiles (Marketed Therapies)
  7. Vertex Pharmaceuticals
  8. CASGEVY
  9. Sickle Cell Disease: Company and Product Profiles (Pipeline Therapies)
  10. Late Stage Products (Phase III)
  11. Pfizer
  12. Inclacumab
  13. Drug profiles in the detailed report…..
  14. Mid Stage Products (Phase II)
  15. Roche
  16. RG 6107
  17. Drug profiles in the detailed report…..
  18. Early Stage Products (Phase I/II)
  19. Beam Therapeutics
  20. BEAM-101
  21. Drug profiles in the detailed report…..
  22. Preclinical and Discovery Stage Products
  23. BRL Medicine
  24. BRL 101
  25. Drug profiles in the detailed report…..
  26. Inactive Products
  27. Sickle Cell Disease- Unmet needs
  28. Sickle Cell Disease – Market drivers and barriers
  29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/sickle-cell-disease-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sickle Cell Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Metastatic Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ companies and 180+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the Metastatic Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Colorectal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Metastatic Colorectal Cancer pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Metastatic Colorectal Cancer Pipeline Report to explore emerging therapies, key Metastatic Colorectal Cancer Companies, and future Metastatic Colorectal Cancer treatment landscapes @ Metastatic Colorectal Cancer Pipeline Outlook Report

Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report

  • In April 2025, Buzzard Pharmaceuticals announced a study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated. Patients must have been treated with available approved treatments already. In this study the investigators are testing a new type of immunotherapy, the potent IL-1 inhibitor isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this treatment to work in this treatment resistant type of tumor.
  • In April 2025, Mirror Biologics Inc. announced a study will assess six different dosing schedules. A standard 3 plus 3 study design will be used. The starting frequency for each dosing schedule will be escalated in subsequent groups of patients. The study will evaluate safety of increased frequency of AlloStim® dosing and anti-tumor effect of the new proposed dose and frequency schedule.
  • In April 2025, Amgen announced a study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
  • DelveInsight’s Metastatic Colorectal Cancer pipeline report depicts a robust space with 150+ active players working to develop 180+ pipeline therapies for Metastatic Colorectal Cancer treatment.
  • The leading Metastatic Colorectal Cancer Companies such as Shanghai Henlius Biotech, Eisai Inc., Treos Bio, AUM Biosciences, Leap Therapeutics, Inc., Hoffmann-La Roche, Replimune, Qilu Pharmaceutical, Lutris Pharma, Ipsen, Bold Therapeutics, Pacylex Pharmaceuticals, FivepHusion, SystImmune, Inspirna, Inc., Sapience Therapeutics, Daiichi Sankyo, Hutchmed, Merus N.V. and others.
  • Promising Metastatic Colorectal Cancer Therapies such as Regorafenib, Cyclophosphamide, Capecitabine, NV1020, MRTX849, Pembrolizumab, Cetuximab, erlotinib, FOLFOX, and others.

Discover how the Metastatic Colorectal Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Metastatic Colorectal Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Metastatic Colorectal Cancer Clinical Trials and Studies

Metastatic Colorectal Cancer Emerging Drugs Profile

  • HLX10 (Serplulimab) + HLX04: Shanghai Henlius Biotech

HLX10, a novel recombinant humanised anti-programmed cell death protein 1 (PD-1) mAb independently developed by Henlius, has the potential to treat a variety of solid tumours. HLX10 has exhibited better pharmacokinetics, pharmacodynamics properties, favourable safety, tolerability profile and anti-tumor activity in preclinical and early clinical research studies. HLX04 is a bevacizumab biosimilar developed by Henlius independently in accordance with Technical Guidelines for the Development and Evaluation of Biosimilars (Tentative), which can be used in the treatment of advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC). HLX04 can block the interaction between vascular endothelial growth factor (VEGF) and its receptors by binding with VEGF specifically, which then inhibits tumour angiogenesis and thus suppressing the growth and metastases of tumours.

  • Lenvatinib: Eisai Inc.

LENVIMA, discovered and developed by Eisai, is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. In syngeneic mouse tumor models, LENVIMA decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone. LENVIMA has been approved for the indications below. Currently the drug is in Phase III stage of its development for the treatment of metastatic colorectal cancer.

  • PEPI1018: Treos Bio

PolyPEPI-1018, Treos’ lead product candidate, is an off-the-shelf immunotherapy in clinical development for the treatment of metastatic colorectal cancer, co-developed with a candidate companion diagnostic. The therapy is in development as a first-line maintenance therapy and as a third-line treatment. The companion diagnostic uses Treos’ proprietary PASCal computational tool to identify Personal EPItopes (PEPIs) that are likely to induce antigen-specific T Cell responses in a patient. In silico trials predicted that these peptides induce exceptionally broad T cell responses against at least 3 tumor-specific antigens in high proportion of patients, without need of biopsy. PolyPEPI1018 was designed to induce polyvalent T cell responses in a large subpopulation of CRC patients using its PEPI TestTM platform which identifies Personal EPItopes (PEPIs) that are likely to induce antigen-specific T cell responses in a subject. Currently the drug is in Phase II stage of its development for the treatment of metastatic colorectal cancer.

  • AUM-001: AUM Biosciences

AUM001 is a highly selective translation inhibitor. It selectively inhibits MNK 1/2 and thereby blocks phosphorylation of eIF4E. This, in turn, interferes with CAP mediated RNA translation, thereby impairing growth signals involved in cancer development, progression, and resistance to therapies. MNK is important in tumor microenvironment (TME) regulation, shifting the balance towards tumor inhibition. Moreover, inhibition of MNK kinases decreases the production of the pro-inflammatory cytokines like TNFα and IL-6, suggesting that MNK kinases and their substrates (eIF4E, hnRNP A1, Spry1/2) play a pivotal role in regulating the innate and adaptive immune compartment. This has the potential to turn “cold” tumors “hot”, increasing the proportion of tumors susceptible to immunotherapies. AUM001 demonstrated encouraging safety, tolerability and target engagement as a monotherapy in two Phase I clinical trials. The global Phase II trial is being conducted in collaboration with MSD, a tradename of Merck & Co., Inc., pursuant to a clinical trial collaboration and supply agreement for KEYTRUDA. Currently, the drug is in the Phase II stage of its development for the treatment of metastatic Colorectal Cancer.

  • DKN-01: Leap Therapeutics, Inc.

Sirexatamab (DKN-01) is an investigational humanized IgG4-kappa monoclonal antibody that targets Dickkopf-related protein 1 (DKK1), a modulator of the Wnt signaling pathway. Overexpression of DKK1 has been associated with tumor progression and poor prognosis in various cancers, including colorectal cancer (CRC). In preclinical studies, DKK1 has been identified as a resistance mechanism to commonly used chemotherapy in colorectal cancer models. By binding to and neutralizing DKK1, sirexatamab aims to restore normal Wnt signaling, thereby inhibiting tumor growth and potentially enhancing the efficacy of other anticancer therapies. Currently the drug is in Phase II stage of its development for the treatment of Metastatic Colorectal cancer.

  • RO7122290: Hoffmann-La Roche

RO7122290is a novel 4-1BB agonist that targets fibroblast activation protein-a (FAP), which is abundantly expressed by cancer-associated fibroblasts in many tumors. Simultaneous binding of FAP and 4-1BB results in clustering and activation of T- and natural killer cells at the tumor site and simultaneous antitumor activity, which has been demonstrated in preclinical models. Upon administration, the FAP/4-1BB-targeting fusion protein RO7122290 targets and binds to both FAP, localized on tumor stromal cells, and 4-1BB, expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. The simultaneous binding of FAP and 4-1BB results in local clustering of FAP-expressing tumor stromal cells and 4-1BB-expressing T-cells, and local immune cell activation through the promotion of T-cell activation, cytokine release and T-cell-mediated anti-tumor immune responses. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. FAP is abundantly expressed by cancer-associated fibroblasts in the majority of solid tumors. The drug is currently in Phase I/II stage of its development for the treatment of metastatic colorectal cancer.

  • E7386: Eisai

E7386 is a CBP / β-catenin inhibitor that inhibits protein-protein interactions between the transcription coactivator CBP and β-catenin, and regulates the Wnt signaling-dependent gene expression. Since E7386 acts on the CBP / β-catenin transcription complex located at the most downstream of the Wnt signaling, it is expected to inhibit not only ligand-dependent activation but also activation caused by gene mutations in Wnt signaling factors such as adenomatous polyposis coli (APC) and β-catenin. E7386 is an orally active selective inhibitor of the interaction between β-catenin and CREB binding protein, which is part of the Wnt/β-catenin signaling pathway, disrupts the Wnt/β-catenin signaling pathway in HEK293 and adenomatous polyposis coli (APC)-mutated human gastric cancer ECC10 cells. In preclinical models, E7386 has demonstrated antitumor activity against mouse mammary tumors developed in Mouse Mammary Tumor Virus (MMTV)-Wnt1 transgenic mice. Currently, the drug is in the Phase I/II stage of its development for the treatment of Metastatic Colorectal Cancer.

The Metastatic Colorectal Cancer pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Colorectal Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Colorectal Cancer Treatment.
  • Metastatic Colorectal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Metastatic Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Colorectal Cancer market.

Get a detailed analysis of the latest innovations in the Metastatic Colorectal Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Metastatic Colorectal Cancer Unmet Needs

Metastatic Colorectal Cancer Companies

Shanghai Henlius Biotech, Eisai Inc., Treos Bio, AUM Biosciences, Leap Therapeutics, Inc., Hoffmann-La Roche, Replimune, Qilu Pharmaceutical, Lutris Pharma, Ipsen, Bold Therapeutics, Pacylex Pharmaceuticals, FivepHusion, SystImmune, Inspirna, Inc., Sapience Therapeutics, Daiichi Sankyo, Hutchmed, Merus N.V. and others.

Metastatic Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

Metastatic Colorectal Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Metastatic Colorectal Cancer Therapies and key Metastatic Colorectal Cancer Developments @ Metastatic Colorectal Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Metastatic Colorectal Cancer Pipeline Report

  • Coverage- Global
  • Metastatic Colorectal Cancer Companies-Shanghai Henlius Biotech, Eisai Inc., Treos Bio, AUM Biosciences, Leap Therapeutics, Inc., Hoffmann-La Roche, Replimune, Qilu Pharmaceutical, Lutris Pharma, Ipsen, Bold Therapeutics, Pacylex Pharmaceuticals, FivepHusion, SystImmune, Inspirna, Inc., Sapience Therapeutics, Daiichi Sankyo, Hutchmed, Merus N.V. and others.
  • Metastatic Colorectal Cancer Therapies- Regorafenib, Cyclophosphamide, Capecitabine, NV1020, MRTX849, Pembrolizumab, Cetuximab, erlotinib, FOLFOX, and others.
  • Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Metastatic Colorectal Cancer drug development? Find out in DelveInsight’s exclusive Metastatic Colorectal Cancer Pipeline Report—access it now! @ Metastatic Colorectal Cancer Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic colorectal cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic colorectal cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Metastatic colorectal cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Lumakras (sotorasib): Amgen
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Axitinib: Pfizer
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. NX 1607: Nurix Therapeutics Inc
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug Name: Company Name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Metastatic colorectal cancer Key Companies
  23. Metastatic colorectal cancer Key Products
  24. Metastatic colorectal cancer- Unmet Needs
  25. Metastatic colorectal cancer- Market Drivers and Barriers
  26. Metastatic colorectal cancer- Future Perspectives and Conclusion
  27. Metastatic Colorectal Cancer Analyst Views
  28. Metastatic Colorectal Cancer Key Companies
  29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Cutaneous T-Cell Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s “Cutaneous T-cell lymphoma Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Cutaneous T-cell lymphoma pipeline landscape. It covers the Cutaneous T-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cutaneous T-Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Cutaneous T-Cell Lymphoma Treatment Landscape. Click here to read more @ Cutaneous T-Cell Lymphoma Pipeline Outlook

Key Takeaways from the Cutaneous T-Cell Lymphoma Pipeline Report

  • In April 2025, Chengdu Zenitar Biomedical Technology Co., Ltd announced a phase IIa Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Purinostat Mesylate for Injection for the Treatment of Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma.
  • In April 2025, Soligenix announced a phase 3 study is to evaluate the ability of an 18-week course of HyBryte and visible light to induce a Treatment Response in patients with patch/plaque phase CTCL compared to patients receiving placebo and visible light.The study will evaluate the efficacy and safety of HyBryte (0.25% hypericin) gel or placebo gel applied twice weekly for 18 weeks.
  • In April 2025, Dren Bio announced a phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas.
  • DelveInsight’s Cutaneous T-Cell Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Cutaneous T-Cell Lymphoma treatment.
  • The leading Cutaneous T-Cell Lymphoma Companies such as HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc​ and others.
  • Promising Cutaneous T-Cell Lymphoma Pipeline Therapies such as E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others.

Stay informed about the cutting-edge advancements in Cutaneous T-Cell Lymphoma Treatments. Download for updates and be a part of the revolution in oncology care @ Cutaneous T-Cell Lymphoma Clinical Trials Assessment

Cutaneous T-cell lymphoma Emerging Drugs

  • HyBryte: Soligenix

HyBryte™ (synthetic hypericin or SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. Synthetic hypericin sodium, the active ingredient in HyBryte™, has Orphan Drug designation in the United States for the treatment of T-cell lymphoma and CTCL and in Europe for CTCL. HyBryte™ has received Fast Track designation for the treatment of cutaneous t-cell lymphoma in the United States.

  • AFM13: Affimed GmbH

AFM-13 is under development for the treatment of refractory and relapsed Hodgkin lymphoma, CD30+ lymphoma such as transformed mycosis fungoides, peripheral and cutaneous T-cell lymphoma, large B-cell lymphoma, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma combination with check point inhibitors and Hodgkin lymphoma combination with lenalidomide. The drug candidate is administered intravenously. AFM-13 is a bi-specific, tetravalent human antibody, it acts by targeting CD30/CD16A. The drug is currently in Phase II stage of its development for the treatment of Cutaneous T Cell Lymphoma.

  • ASTX660: Otsuka Pharmaceutical Co., Ltd

ASTX660 (Tolinapant) is a novel, orally administered, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Inhibitors of apoptosis proteins (IAPs) are frequently overexpressed in tumor cells and contribute to tumor cell survival and chemo-resistance. By inhibiting IAPs, tolinapant promotes cell death. Tolinapant also acts via a newly described immunomodulatory mechanism, which works to enhance an anti-tumor immune response in T-cell lymphomas. The drug is in Phase I/II for the treatment of CTCL.

  • WUCART007: Wugen

WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies. Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T-cell receptor alpha constant (TRAC), preventing CAR-T cell fratricide and mitigating the risk of graft-versus-host-disease (GvHD). WU-CART-007 is manufactured using healthy donor-derived T-cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. Currently, the drug is in Phase I stage of its clinical trial for the treatment of CTCL.

The Cutaneous T-Cell Lymphoma pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous T-Cell Lymphoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous T-Cell Lymphoma Treatment.
  • Cutaneous T-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Cutaneous T-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous T-Cell Lymphoma market.

Get a detailed analysis of the latest innovations in the Cutaneous T-Cell Lymphoma pipeline. Explore DelveInsight’s expert-driven report today! @ Cutaneous T-Cell Lymphoma Unmet Needs

Cutaneous T-Cell Lymphoma Companies

HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc​ and others.

Cutaneous T-cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Cutaneous T-Cell Lymphoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in Cutaneous T-Cell Lymphoma Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Cutaneous T-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Cutaneous T-Cell Lymphoma Pipeline Report

  • Coverage- Global
  • Cutaneous T-Cell Lymphoma Companies- HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others.
  • Cutaneous T-Cell Lymphoma Pipeline Therapies- E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others.
  • Cutaneous T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Cutaneous T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Cutaneous T-Cell Lymphoma Pipeline on our website @ Cutaneous T-Cell Lymphoma Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Cutaneous T-cell lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Cutaneous T-cell lymphoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug Name: Company Name
  9. Mid Stage Products (Phase II)
  10. AFM13: Affimed GmbH
  11. Early Stage Products (Phase I)
  12. WUCART007: Wugen
  13. Preclinical Stage Products
  14. Drug Name: Company Name
  15. Inactive Products
  16. Cutaneous T-cell lymphoma Key Companies
  17. Cutaneous T-cell lymphoma Key Products
  18. Cutaneous T-cell lymphoma- Unmet Needs
  19. Cutaneous T-cell lymphoma- Market Drivers and Barriers
  20. Cutaneous T-cell lymphoma- Future Perspectives and Conclusion
  21. Cutaneous T-cell lymphoma Analyst Views
  22. Cutaneous T-cell lymphoma Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cutaneous T-Cell Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies